• 1
    Nomura AMY, Kolonel LN. Prostate cancer: a current perspective. Epidemiol Rev 1991; 13: 20026.
  • 2
    Meikle AW, Smith JA Jr. Epidemiology of prostate cancer. Urol Clin North Am 1990; 17: 70918.
  • 3
    Nomura A, Heilbrun LK, Stemmermann GN, Judd HL. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 1988; 48: 35157.
  • 4
    Barrett-Connor E, Garland C, McPhillips JB, Khaw K-T, Wingard DL. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res 1990; 50: 16973.
  • 5
    Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev 1993; 2: 2732.
  • 6
    Nomura AMY, Stemmermann GN, Chyou PH, Henderson BE, Stanczyk FZ. Serum androgens and prostate cancer. Cancer Epidemiol Biomarkers Prev 1996; 5: 6215.
  • 7
    Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1998; 88: 111826.
  • 8
    Knekt P, Aromaa A, Maatela J, Aaran R-K, Nikkari T, Hakama M, et al. Serum vitamin E and risk of cancer among Finnish men during a 10-year follow-up. Am J Epidemiol 1988; 127: 2841.
  • 9
    Teppo L, Pukkala E, Hakama M, Hakulinen T, Herva A, Saxen E. Way of life and cancer incidence in Finland. A municipality-based ecological analysis. Scand J Soc Med 1980; (Suppl 19): 184.
  • 10
    Breslow NE, Day NE. Statistical methods in cancer research. Volume 1. The analysis of case-control studies. IARC Scientific Pub. No. 32. Lyon, France: IARC Scientific Publications, 1980.
  • 11
    Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev 1993; 15: 4865.
  • 12
    Lookingbill DP, Demers LM, Wang C, Leung A, Rittmaster RS, Santen RJ. Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J Clin Endrocrinol Metab 1991; 72: 12428.